Advancement of artificial intelligence based treatment strategy in type 2 diabetes: A critical update.
10.1016/j.jpha.2025.101305
- Author:
Aniruddha SEN
1
;
Palani Selvam MOHANRAJ
2
;
Vijaya LAXMI
2
;
Sumel ASHIQUE
3
;
Rajalakshimi VASUDEVAN
4
;
Afaf ALDAHISH
4
;
Anupriya VELU
5
;
Arani DAS
6
;
Iman EHSAN
7
;
Anas ISLAM
8
;
Sabina YASMIN
9
;
Mohammad Yousuf ANSARI
10
Author Information
1. Department of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, 273008, India.
2. Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, 273008, India.
3. Department of Pharmaceutical Technology, Bharat Technology, Uluberia, 711316, India.
4. Department of Pharmacology and Toxicology, College of Pharmacy, King Khalid University, Abha, 62529, Saudi Arabia.
5. Department of Biochemistry, Mahayogi Gorakhnath University, Gorakhpur, 273008, India.
6. Department of Physiology, All India Institute of Medical Sciences, Gorakhpur, 273008, India.
7. National Institute of Pharmaceutical Education and Research, Kolkata, 700054, India.
8. Faculty of Pharmacy, Integral University, Lucknow, 226026, India.
9. Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, 62529, Saudi Arabia.
10. Ibne Seena College of Pharmacy, Azmi Vidya Nagri Anjhi Shahabad, Hardoi, 241124, India.
- Publication Type:Review
- Keywords:
Artificial intelligence;
Personalized therapy;
Therapeutics;
Type 2 diabetes mellitus
- From:
Journal of Pharmaceutical Analysis
2025;15(6):101305-101305
- CountryChina
- Language:English
-
Abstract:
In the unrelenting race to strive to dominate type 2 diabetes mellitus (T2DM) care better, this review paper sets out on a significant discovery trip across recent advancements in treatment and the blooming era of artificial intelligence (AI) utilities. Given the considerable global burden of T2DM, innovative therapeutic approaches to improve patient outcomes remain a public health priority. This review first provides an in-depth analysis of the current state of therapy, from novel pharmacotherapy to lifestyle interventions and new treatment methods. At the same time, the rapidly increasing role of AI in diabetes care is woven into the story, mainly targeting how insulin therapy can be modified and personalized through algorithms and predictive modelling. It leaves a deep review of their pre-existing synergies, which helps understand how collaborative opportunities will unlock the future of T2DM care. This critical role is shown by integrating recent therapeutic advances and AI with overall showcasing better screening, diagnosis, and therapeutics decision-making to outcome prediction in T2DM. The review emphasizes how AI applications in insulin therapy have transformative potential in diabetes care. These person-centred approaches to T2DM management, which are more effective and personalized than some traditional strategies, only work because of the often-hidden synergies between AI algorithms in areas such as diagnostic criteria, predictive methods, and familiar classification tools for subgroups with relevant aspects/predictors on prognosis or treatment responsiveness.
